References: Hair growth and hair loss
J Cutan Pathol. 1975;2(1):35-41.
Modulation of dermal cell activity during hair growth in the rat.
Pierard GE, de la Brassinne M.
Interaction between connective tissue cells and hair growth in the rat has been studied by radioautography after in vivo and in vitro pulse labelling with thymidine, uridine, histidine, leucine and proline. The connective tissue, which surrounds and integrates the hair bulbs as a unit, contains cells of various types which have a cyclic metabolic activity. This cyclic activity is coordinated with the hair growth cycle. The number of nuclei which actively synthesize DNA in the dermal cells, mainly those of endothelial and migratory cells, significantly increases during the short and transient anagen 4 substage. RNA and protein synthesizing activities are also present in all cell types and seem modulated by the hair cycle although to a lesser degree. This data provides an important basis for the interpretation of similar studies in alopecia areata.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1225936&dopt=Abstract
J Bras Ginecol. 1984 Mar;94(3):91-7.
[A new ovulation inhibitor antiandrogen]
[Article in Spanish]
Millet-part A, Blanes-espi A, Ferrer-barriendos J, Siqueira L, Acosta E.
PIP: Cyproterone acetate (Androcur), a potent progestagin and antigonadotropin, has been widely used in Europe in treatment of hirsutism, seborrhea, and alopecia. A formulation combining an estrogen, ethinyl estradiol (EE), to neutralize the progestational action and consequent amenorrhea of Androcur is marketed under the name of DIANE. 3 different treatment protocols were tested: 1) continuous administration of Androcur at doses varying from 25-150 mgr with rests every 3 months 2) high dose combination of 50 mgr Androcur and .05 mgr of EE in 21 day cycles and 3) low dose combinations of 2 mgr Androcur and .05 mgr of EE in 21-day cycles (DIANE). 54 patients who received the DIANE combined low dose treatment were compared. 7 of them had previously received the cyproterone acetate in variable doses of 25-150 mgr/day for 3-10 cycles, 16 had previously taken cyproterone acetate in variable doses of 50-150 mgr/day for 3-14 cycles, followed by the high dose combined method for 3-12 cycles and DIANE for 1-7 cycles, and 15 patients had previously received the high dose combined method for 2-22 cycles followed by DIANE for 3-7 cycles. Among the 54 patients there were 10 cases of idiopathic hirsutism, 11 of suprarenal hirsutism, 25 of ovarian hirsutism, 2 of iatrogenic hirsutism, 24 of acne, 37 of seborrhea, and 10 of alopecia. No pregnancies were reported in patients exposed to risk of pregnancy who took a total of 96 cycles of DIANE or 55 cycles of the high dose combination. Continuous dose cyproterone acetate is usually associated with amenorrhea. The high dose combination induces amenorrhea in up to 20% of cases, while with DIANE the principal change is a diminution in the amount of bleeding. Cyproterone acetate alone or associated with androgens is the preferred treatment for androgenic manifestations. The therapeutic regimen should be adapted to the predominance, time of evolution and severity of symptoms. For moderate or serious hirsutism, the treatment should be continuous administration of high doses of cyproterone acetate for 6 months followed by the combined method at high doses according to the type of initial response. When acne and seborrhea predominate, the combined low-dose method is used, because even though the high dose continuous method gives better results, the secondary effects do not justify its use. The high dose continuous method can be chosen if the low dose combined method fails. The high dose combined method is preferred for alopecia, with the low dose combined method used for maintenance.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12266391&dopt=Abstract
Contracept Fertil Sex (Paris). 1985 Dec;13(12):1265-8.
[Hair loss during treatment with oral contraceptives]
[Article in French]
Lehucher-ceyrac D, Weber-buisset, Puissant A.
Oral contraceptives with a dominant androgen component can cause or worsen androgen-dependent alopecia in women. This diagnosis can only be made if other causes of alopecia (which can occur at the same time as treatment with oral contraceptives) have been excluded. The patient's endocrine profile must be investigated sometimes, this being in order to detect any excess production of androgens. These types of alopecia call for the stopping of the oral contraceptive and sometimes also calls for oral anti-antigen treatment.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12267514&dopt=Abstract
Natural Herbal Supplements ||
Hair Million herbal formula for hair loss and hair growth ||
Hair growth research references ||
Online Pharmacy : discount prescription medication ||